Pembrolizumab plus chemotherapy cost-effectiveness at additional modelled price points
| Parameter | Base case model analysis* | |
| WTP value, $/QALY | 100 000 | 15 000 |
| Nivolumab cost, $/mg | 12.05 | 31.38 |
| Total cost, $ | 176 197 | 235 651 |
| QALYs | 1.61 | 1.61 |
| ICER, $/QALY | 99 915 | 149 907 |
*Only the cost of pembrolizumab was varied.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; WTP, Willingness-to-pay.